You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Expansion of Immuno-CometChip Platform
SBC: AMELIA TECHNOLOGIES LLC Topic: NIEHSProject SummaryThe objective of this supplementation request is to further our recent advances in the development of thewell Immuno CometChip assay results and build a prototypewell preformer giving the assay more utility and increasing commercial viability
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples
SBC: CIRCA BIOSCIENCE LLC Topic: 102Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil
SBC: AcePre, LLC Topic: NCCIHPROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Software and services to advance dose-response modeling in chemical risk assesment
SBC: KS & ASSOCIATES LLC Topic: NCATSPROJECT SUMMARY Chemical risk assessment has been widely applied in chemical industry as a necessary step to get new commercial chemicals registeredand in governmental agencies as a critical procedure to evaluate the toxicity of chemicals in order to properly regulate them to protect human health and the environmentThe Lautenberg Chemical Safety Act further strengthens the importance of chemical r ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Chronic intrapulmonary delivery of a novel small molecule Wnt/beta-catenin inhibitor for Idiopathic Pulmonary Fibrosis
SBC: BETA CAT PHARMACEUTICALS, INC. Topic: NHLBIProject Summary Idiopathic pulmonary fibrosisIPFis a devastatingprogressive disease with no known cure and no treatment that convincingly alters the disease course or significantly improves mortalityThe objective of this proposal is the development of nebulized delivery of the small molecule inhibitor of Wntcatenin signalingBCfor Idiopathic Pulmonary FibrosisPre clinical studies in rodentsdogsand ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Catheter Development for Epicardial Atrial Gene Painting
SBC: RITHIM BIOLOGICS INC Topic: NCATSABSTRACT Atrial fibrillationAFis the most common rhythm disturbance in the US and other developed countriesAF significantly affects the lives of the afflictedcausing symptoms that range from palpitations to fatigueweakness and activity intoleranceand substantially increasing the risks of strokecongestive heart failure and deathThe impact on public health is substantialwith more thanhospital admiss ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
MRI-compatible and integrated devices for simultaneous neural recording, stimulation, imaging
SBC: MR-LINK LLC Topic: 101Project Summary The use of technologies for imagingrecording and modulating brain activity is rapidly advancing neuroscienceNotablymicroelectrodes are used to locally record neural activity or to perturb circuit functionFunctional magnetic resonance imagingfMRIis widely used to image large scale patterns of hemodynamic fluctuations accompanying neural activityAlthough these techniques have become ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Mitigation of Acute and Chronic Kidney Injuries by Systemic Infusion of Adipose-Derived Soluble Therapeutic Factor Concentrate
SBC: NeuroFx, Inc. Topic: 300ABSTRACT Acute kidney injuryAKIis a syndrome characterized by rapid loss of the kidneyandapos s excretory functionAKI is the leading cause of nephrology consultation and results inmillion hospital admissions a yearThe socioeconomic impact of AKI is significantresulting in $billion cost to the health care systemDespite the high rate of incidence of AKIno therapy currently existsother than supportiv ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health